PMID- 35664415
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 14
IP  - 4
DP  - 2022 Apr
TI  - Serum Adiponectin and Nitric Oxide Levels in Type II Diabetes and Its Correlation 
      With Lipid Profile.
PG  - e24613
LID - 10.7759/cureus.24613 [doi]
LID - e24613
AB  - Introduction Various markers for diabetes have been identified in this new era of 
      medicine, the most recent being adiponectin, which is primarily secreted from 
      adipose tissue and has anti-diabetic, anti-inflammatory, and anti-atherogenic 
      properties. It is also known to increase insulin sensitivity. Adiponectin 
      deficiency or decreased secretion causes a variety of complications, including 
      insulin resistance and the onset of type 2 diabetes mellitus (T2DM). One such 
      complication of T2DM is endothelial dysfunction, which leads to decreased 
      synthesis of nitric oxide (NO), another potent marker that normally disrupts key 
      events in the progression of atherosclerosis. Aims and objectives The aim of the 
      study was to compare and correlate serum adiponectin and nitric oxide levels with 
      glycemic status in patients with T2DM and healthy controls. Materials and methods 
      This comparative cross-sectional study included known cases of type II diabetes 
      under group I and healthy age-matched controls under group II. Serum levels of 
      adiponectin and nitric oxide were assessed in both the groups along with glycemic 
      status [fasting blood sugar (FBS) and glycated hemoglobin (HbA1c)] and these 
      parameters were compared between both groups using a t-test. Adiponectin and NO 
      levels were correlated using Pearson's correlation with glycemic status in group 
      I. Results The mean adiponectin levels in group I were 5.94 +/- 1.490 mug/mL, which 
      was significantly (p<0.00) less than in group II, 10.30 +/-1.669 mug/mL. The mean NO 
      levels in group I (42.98 +/- 6.300 mumol/L) were also significantly (p<0.00) less 
      than in group II (56.126 +/- 7.579 mumol/L). FBS and HbA1C levels were significantly 
      higher in group I than in group II. Conclusion Adiponectin and NO levels were 
      significantly reduced in individuals with T2DM when compared to healthy controls. 
      Therapeutic interventions that increase adiponectin and NO levels may be useful 
      targets for improving diabetes control and reducing complications.
CI  - Copyright (c) 2022, Tuppad et al.
FAU - Tuppad, Sangeeta
AU  - Tuppad S
AD  - Physiology, Koppal Institute of Medical Sciences, Koppal, IND.
FAU - Medala, Kalpana
AU  - Medala K
AD  - Physiology, All India Institute of Medical Sciences, Bibinagar, Hyderabad, IND.
FAU - Umesh, Madhusudhan
AU  - Umesh M
AD  - Physiology, All India Institute of Medical Sciences, Bibinagar, Hyderabad, IND.
FAU - Gaur, Archana
AU  - Gaur A
AD  - Physiology, All India Institute of Medical Sciences, Bibinagar, Hyderabad, IND.
FAU - Ganji, Vidya
AU  - Ganji V
AD  - Physiology, All India Institute of Medical Sciences, Bibinagar, Hyderabad, IND.
FAU - Sakthivadivel, Varatharajan
AU  - Sakthivadivel V
AD  - Internal Medicine, All India Institute of Medical Sciences, Bibinagar, Hyderabad, 
      IND.
FAU - Kumar, Prakash
AU  - Kumar P
AD  - Physiology, Koppal Institute of Medical Sciences, Koppal, IND.
LA  - eng
PT  - Journal Article
DEP - 20220430
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC9149778
OTO - NOTNLM
OT  - adiponectin
OT  - antidiabetic
OT  - biomarkers
OT  - diabetes mellitus
OT  - endothelial dysfunction
OT  - no
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/06/07 06:00
MHDA- 2022/06/07 06:01
PMCR- 2022/04/30
CRDT- 2022/06/06 14:13
PHST- 2022/04/29 00:00 [accepted]
PHST- 2022/06/06 14:13 [entrez]
PHST- 2022/06/07 06:00 [pubmed]
PHST- 2022/06/07 06:01 [medline]
PHST- 2022/04/30 00:00 [pmc-release]
AID - 10.7759/cureus.24613 [doi]
PST - epublish
SO  - Cureus. 2022 Apr 30;14(4):e24613. doi: 10.7759/cureus.24613. eCollection 2022 
      Apr.